Neuraxis CEO buys 8,060 shares in open market

Neuraxis, INC Chief Executive Officer Brian Allen Carrico purchased additional company stock in the open market.

Rhea-AI Filing Summary

Neuraxis, INC Chief Executive Officer Brian Allen Carrico purchased additional company stock in the open market. On April 1, 2026, he bought 8,060 shares of Neuraxis common stock at $1.96 per share.

After this transaction, Carrico directly owns 348,178 shares of Neuraxis common stock, modestly increasing his personal stake in the company.

Insights

Equity governance analyst

CEO makes a modest open-market share purchase, slightly increasing direct ownership.

The Chief Executive Officer of Neuraxis, INC, Brian Allen Carrico, executed an open-market purchase of 8,060 shares of common stock at $1.96 per share on April 1, 2026. This is a straightforward cash purchase rather than an option exercise or stock grant.

Following the trade, Carrico directly holds 348,178 shares of Neuraxis common stock. The filing shows a net-buy pattern with no concurrent sales or derivative exercises and no remaining derivative positions listed, suggesting this is a routine, incremental increase in ownership rather than a transformational transaction.

Insider Trade Summary

Net Buyer: 8,060 shares

Net Buy 1 txn

Insider Carrico Brian Allen

Role Chief Executive Officer

Bought 8,060 shs ($16K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	8,060	$1.96	$16K

Holdings After Transaction: Common Stock — 348,178 shares (Direct)

Key Figures

Shares purchased: 8,060 shares Purchase price: $1.96 per share Shares owned after transaction: 348,178 shares +1 more

4 metrics

Shares purchased 8,060 shares Open-market common stock purchase on April 1, 2026

Purchase price $1.96 per share Price paid in the April 1, 2026 open-market trade

Shares owned after transaction 348,178 shares CEO’s direct Neuraxis common stock holdings post-transaction

Net buy shares 8,060 shares Net-buy direction in transaction summary for this Form 4

Key Terms

open-market purchase, Common Stock, Form 4, direct ownership

4 terms

open-market purchase financial

"transaction_action": "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

direct ownership financial

""direct_or_indirect": "D""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Neuraxis (NRXS) report for its CEO?

Neuraxis reported that CEO Brian Allen Carrico completed an open-market purchase of 8,060 shares of the company’s common stock at $1.96 per share. This increased his directly held stake, as disclosed in the Form 4 insider trading report.

How many Neuraxis (NRXS) shares does the CEO own after this Form 4?

After the reported transaction, Neuraxis CEO Brian Allen Carrico directly owns 348,178 shares of the company’s common stock. This total reflects his position following the open-market purchase of 8,060 shares at $1.96 per share on April 1, 2026.

Was the Neuraxis (NRXS) CEO’s recent trade a purchase or a sale?

The Neuraxis CEO’s recent trade was a purchase. Brian Allen Carrico bought 8,060 shares of Neuraxis common stock in an open-market transaction at $1.96 per share, with no sales reported in this Form 4 filing.

What price did Neuraxis (NRXS) CEO Brian Allen Carrico pay per share?

Brian Allen Carrico paid $1.96 per share for Neuraxis common stock in his open-market purchase. The transaction involved acquiring 8,060 shares and was reported as a non-derivative purchase on the Form 4 insider trading report.

Does the Neuraxis (NRXS) Form 4 show any derivative or option activity?

The Form 4 does not show any derivative or option transactions. It reports only a non-derivative open-market purchase of 8,060 shares of Neuraxis common stock by CEO Brian Allen Carrico, with derivative holdings listed as empty in the derivative summary.

Is the Neuraxis (NRXS) CEO’s ownership direct or through an entity?

The Form 4 indicates that Brian Allen Carrico’s reported Neuraxis holdings are held directly. The transaction is coded as direct ownership, and the nature of ownership field is blank, suggesting no intermediary entity such as a trust or partnership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/03/2026 - 11:19 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carrico Brian Allen

(Last) (First) (Middle)

11611 N. MERIDIAN ST, SUITE 330

(Street)

CARMEL INDIANA 46032

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Neuraxis, INC [ NRXS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		P		8,060	A	$1.96	348,178	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Brian Carrico	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)